These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
36 related articles for article (PubMed ID: 8028439)
1. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143 [TBL] [Abstract][Full Text] [Related]
2. Molecular targets in oncology: implications of the multidrug resistance gene. Lum BL; Gosland MP; Kaubisch S; Sikic BI Pharmacotherapy; 1993; 13(2):88-109. PubMed ID: 8097038 [TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance in haematological malignancies. Jiang XR; Macey MG; Newland AC Med Lab Sci; 1991 Oct; 48(4):261-70. PubMed ID: 1687419 [TBL] [Abstract][Full Text] [Related]
4. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance. Minderman H; Vanhoefer U; Toth K; Minderman MD; Rustum YM Cancer; 1996 Dec; 78(11):2427-36. PubMed ID: 8941015 [TBL] [Abstract][Full Text] [Related]
5. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells. Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039 [TBL] [Abstract][Full Text] [Related]
6. Differences in sensitivity to UVC, UVB and UVA radiation of a multidrug-resistant cell line overexpressing P-glycoprotein. Trindade GS; Capella MA; Capella LS; Affonso-Mitidieri OR; Rumjanek VM Photochem Photobiol; 1999 Jun; 69(6):694-9. PubMed ID: 10378008 [TBL] [Abstract][Full Text] [Related]
7. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line. Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825 [TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein, multidrug resistance and protein kinase C. Fine RL; Chambers TC; Sachs CW Stem Cells; 1996 Jan; 14(1):47-55. PubMed ID: 8820951 [TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Kaye SB Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854 [TBL] [Abstract][Full Text] [Related]
11. Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Serra M; Scotlandi K; Manara MC; Maurici D; Lollini PL; De Giovanni C; Toffoli G; Baldini N Anticancer Res; 1993; 13(2):323-9. PubMed ID: 8100126 [TBL] [Abstract][Full Text] [Related]
12. Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter. Marthinet E; Divita G; Bernaud J; Rigal D; Baggetto LG Gene Ther; 2000 Jul; 7(14):1224-33. PubMed ID: 10918491 [TBL] [Abstract][Full Text] [Related]
13. Bis-pyranobenzoquinones as a new family of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in mammalian cells and the protozoan parasite Leishmania. Jiménez-Alonso S; Pérez-Lomas AL; Estévez-Braun A; Muñoz Martinez F; Chávez Orellana H; Ravelo AG; Gamarro F; Castanys S; López M J Med Chem; 2008 Nov; 51(22):7132-43. PubMed ID: 18954040 [TBL] [Abstract][Full Text] [Related]